Aduro Acquires GVAX Vaccines, Plans for Combinations
California-based Aduro Biotech is ready to combine two recently acquired GVAX cancer vaccines with its listeria-based vaccine in order to produce a potent non-antibody combination vaccine. According to Aduro, the GVAX technology is an excellent component in combination vaccines as it secretes genetically modified granulocyte-macrophage colony-stimulating factor (GM-CSF) which, once in the body, rapidly increase the number or white blood cells to fight infection.